Fate Therapeutics
Primary Menu
Skip to content
About Us
Our Mission
Our Cells of Interest
Management
Board of Directors
Pipeline
Overview
Immuno-Oncology Candidates
FT500
FT516
FT596
FT538
FT576
FT819
Immuno-Regulation Candidates
ProTmune
™
FT301
Science
Ex Vivo
Cell Modulation
iPSC Platform
Manufacturing
Publications
Collaborations
Join Our Team
Vision, Mission, Values
Working at Fate
Career Opportunities
Investors
Overview
Press Releases
Events & Presentations
Financials & Filings
SEC Filings
Annual Reports and Proxies
Corporate Governance
Stock Information
Historical Stock Lookup
Investors FAQs
Contact
About Us
Our Mission
Our Cells of Interest
Management
Board of Directors
Pipeline
Overview
Immuno-Oncology Candidates
FT500
FT516
FT596
FT538
FT576
FT819
Immuno-Regulation Candidates
ProTmune
™
FT301
Science
Ex Vivo
Cell Modulation
iPSC Platform
Manufacturing
Publications
Collaborations
Join Our Team
Vision, Mission, Values
Working at Fate
Career Opportunities
Investors
Overview
Press Releases
Events & Presentations
Financials & Filings
SEC Filings
Annual Reports and Proxies
Corporate Governance
Stock Information
Historical Stock Lookup
Investors FAQs
Contact
2017
,
conference
Novel Strategies to Activate and Target NK Cells for Cancer
About Us
Our Mission
Our Cells of Interest
Management
Board of Directors
Pipeline
Overview
Immuno-Oncology Candidates
FT500
FT516
FT596
FT538
FT576
FT819
Immuno-Regulation Candidates
ProTmune
™
FT301
Science
Ex Vivo
Cell Modulation
iPSC Platform
Manufacturing
Publications
Collaborations
Join Our Team
Vision, Mission, Values
Working at Fate
Career Opportunities
Investors
Overview
Press Releases
Events & Presentations
Financials & Filings
SEC Filings
Annual Reports and Proxies
Corporate Governance
Stock Information
Historical Stock Lookup
Investors FAQs
Contact
